Zurich, January 24, 2026, 20:57 CET — The market has closed.
Novartis AG’s stock closed Friday at 115.64 Swiss francs, gaining 0.54 franc, or 0.47%. It swung between 114.70 and 116.04 during the session. Roughly 2.6 million shares traded hands. Yahoo Finance
Novartis (NOVN.S) closed near the upper edge of its 52-week range, just shy of the 116.78 francs mark. This level often prompts investors to scrutinize the outlook more closely. Investing.com
As the market remains closed for the weekend, attention turns to whether this move was just a defensive reaction or a premature bet ahead of the firm’s upcoming update. Either way, it sets higher expectations for the next batch of numbers and guidance.
The Swiss Market Index dipped 0.61% on Friday, with Novartis among the major stocks that softened the decline. Yahoo Finance
Stocks fell across Europe to close out the week, weighed down by ongoing tariff concerns and geopolitical tensions, Reuters reported. Michael Field, Morningstar’s chief European equity strategist, noted, “We’ve seen a general increase in uncertainty this year around the global economy, politics and geopolitics.” Reuters
In New York, Novartis’ U.S.-listed shares (NVS) ended Friday at $147.14, up 1.48%, then ticked higher to $147.90 in after-hours trading, according to StockAnalysis data. StockAnalysis
Novartis lists its ordinary shares on the SIX Swiss Exchange, priced in Swiss francs. Its ADRs, meanwhile, are available on the New York Stock Exchange and quoted in dollars, according to the company’s investor materials. Novartis
The risk is still there: the patent cliff, when exclusivity expires and generics take a chunk. Novartis has flagged generic competition eating into sales of its heart-failure drug Entresto, a concern investors repeatedly highlight. Reuters
There’s a more straightforward risk at play. When sentiment sours and funds exit equities, defensive stocks can still fall—just not as steeply as cyclicals.
Novartis will release its fourth-quarter and full-year 2025 results on Feb. 4. Investors will be watching closely for guidance, insights on the portfolio, and clues on whether the current share-price momentum can hold up. Novartis
